Thompson Siegel & Walmsley LLC Has $58.99 Million Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Thompson Siegel & Walmsley LLC trimmed its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 15.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 852,419 shares of the company’s stock after selling 150,622 shares during the quarter. Thompson Siegel & Walmsley LLC owned about 0.68% of Henry Schein worth $58,987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in shares of Henry Schein by 23.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after acquiring an additional 143 shares in the last quarter. CIBC Asset Management Inc grew its holdings in Henry Schein by 1.0% during the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company’s stock valued at $1,235,000 after purchasing an additional 169 shares during the period. Studio Investment Management LLC grew its holdings in Henry Schein by 3.8% during the third quarter. Studio Investment Management LLC now owns 4,674 shares of the company’s stock valued at $341,000 after purchasing an additional 172 shares during the period. Metis Global Partners LLC grew its holdings in Henry Schein by 4.7% during the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company’s stock valued at $291,000 after purchasing an additional 187 shares during the period. Finally, Central Pacific Bank Trust Division grew its holdings in Henry Schein by 2.0% during the fourth quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company’s stock valued at $706,000 after purchasing an additional 200 shares during the period. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Trading Down 4.1 %

Shares of HSIC stock opened at $69.94 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. Henry Schein, Inc. has a 52-week low of $63.67 and a 52-week high of $82.49. The company has a market capitalization of $8.68 billion, a PE ratio of 28.78, a price-to-earnings-growth ratio of 2.13 and a beta of 0.90. The business’s fifty day moving average is $74.77 and its 200 day moving average is $72.64.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter last year, the business posted $0.66 EPS. The company’s quarterly revenue was up 5.8% on a year-over-year basis. On average, equities research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Barrington Research reissued an “outperform” rating and set a $90.00 price objective on shares of Henry Schein in a report on Wednesday, February 26th. UBS Group reduced their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday, February 26th. Wells Fargo & Company assumed coverage on Henry Schein in a report on Friday, February 14th. They set an “equal weight” rating and a $80.00 price objective for the company. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and increased their price objective for the company from $69.00 to $84.00 in a report on Monday, January 6th. Finally, Jefferies Financial Group increased their target price on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $81.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.